Athira Pharma to Participate in Panel Discussion at Sachs 4th Annual Neuroscience Innovation Forum

Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company, announced that CEO Leen Kawas, Ph.D., will participate in the Sachs 4th Annual Neuroscience Innovation Forum on April 28, 2021, at 8:30 a.m. PT. The panel titled “Progress in Alzheimer’s and Dementia” will focus on advancements in treating neurodegenerative diseases. The event will also feature notable experts from AZTherapies, NIH, Johnson & Johnson Innovation, and more. A recording will be available starting May 26, and further details can be found on Athira's website.

BOTHELL, Wash., April 21, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a virtual panel discussion at the Sachs 4^th Annual Neuroscience Innovation Forum. The panel, titled “Progress in Alzheimer’s and Dementia,” will be aired on Wednesday, April 28, 2021, at 8:30 a.m. PT /11:30 a.m. ET.

The panel will be moderated by Howard Fillit, M.D., Founding Executive Director at the Alzheimer’s Drug Discovery Foundation, and Paul Matteis, Managing Director at Stifel, and will include a discussion with the following participants:

• David Elmaleh, Ph.D., Chairman and Chief Scientific Officer, AZTherapies
• Todd Haim, Ph.D., Chief, Office of Small Business Research, National Institute on Aging (NIH)
• Leen Kawas, Ph.D., President and Chief Executive Officer, Athira Pharma
• Gregor Macdonald, Ph.D., Senior Director, Neuroscience Scientific Licensing, Johnson & Johnson Innovation
• Deborah Rathjen, Ph.D., Executive Chair, Bioasis Technologies
• Susanne Wilke, Ph.D., President and Chief Executive Officer, Cognoptix

To register in advance for a live webcast of the panel discussion, please click here. For more information about the Sachs 4^th Annual Neuroscience Innovation Forum, please refer to the conference portal.

Beginning May 26, a recording of the panel will be available on the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay will be available for at least 30 days.

About Athira Pharma, Inc.
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

FAQ

What is the date of the Sachs 4th Annual Neuroscience Innovation Forum involving Athira Pharma?

The Forum will be held on April 28, 2021.

Who will represent Athira Pharma at the 4th Annual Neuroscience Innovation Forum?

Leen Kawas, Ph.D., the CEO of Athira Pharma, will represent the company.

What is the focus topic of the panel discussion at the Neuroscience Innovation Forum?

The panel discussion will focus on 'Progress in Alzheimer’s and Dementia.'

When will a recording of the panel discussion be available?

A recording will be available starting May 26, 2021.

How can I register for the live webcast of the Athira Pharma panel discussion?

You can register for the live webcast through the link provided in the press release.

What is ATH-1017 in relation to Athira Pharma?

ATH-1017 is Athira's lead therapeutic candidate, aimed at treating Alzheimer’s and Parkinson’s dementia.